Strategic Partners A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OZYMF research report →
Price Chart
About the company
Strategic Partners A/S currently conducts minimal business operations. Its previous activities centered on the field of biotechnology. The firm, originally known as Orphazyme A/S, adopted the new moniker Strategic Partners A/S in October 2024.
- CEO
- Jakob Færch Bendtsen
- IPO
- 2019
- Employees
- 1
- HQ
- Herlev, CR, DK
Get TickerSpark's AI analysis on OZYMF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.84M
- P/E
- 17.65
- PEG
- 0.03
- P/S
- 57.63
- P/B
- 1.23
- EV/EBITDA
- -12.21
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -470.66%
- Net Margin
- 329.34%
- ROE
- 7.13%
- ROIC
- -9.92%
Latest fiscal year · YoY change
- Revenue
- $309.00K+0.0%
- Gross Profit
- $309.00K+0.0%
- Op Income
- $-2,446,000
- Net Income
- $-859,000-288155.0%
- EPS
- $-21.00-162.5%
- OCF Growth
- +36.6%
- FCF Growth
- +36.6%
- 52W High
- $90.00
- 52W Low
- $0.09
- 50D MA
- $90.00
- 200D MA
- $90.00
- Beta
- 0.29
- RSI (14)
- 100
- Avg Volume
- 1.88K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Orphazyme said the first half was dominated by the FDA CRL for arimoclomol, followed by a sharp restructuring to conserve cash and keep the NPC approval path alive in Europe and the U.S.· August 31, 2021
- Management said the company is now focused solely on arimoclomol for NPC, with ALS and IBM programs discontinued.
- A restructuring launched in June is expected to cut total operating expenses by about 60% while preserving core regulatory, medical, and pre-commercial capabilities.
- Early Access Program activity continued, with more than 100 patients enrolled across the U.S., Germany, and France.
- EMA review is ongoing, with a CHMP opinion expected by the end of 2021 and potential marketing authorization in early 2022.
- The company said it will seek a Type-A meeting with the FDA in the coming weeks and is exploring financing options to fund commercialization.
For the first half of 2021, Orphazyme reported net revenues of DKK 13.2 million, driven by sales of arimoclomol in France under the remunerated Early Access Program. Operating expenses were DKK 479 million, including R&D expenses of DKK 265 million, and the company reported a net loss of DKK 454 million. Cash at June 30, 2021 was DKK 334 million, down from DKK 727 million at the end of December 2020. For 2021, management reiterated guidance for net revenues of DKK 30 million to DKK 40 million from the French EAP, and said operating loss, operating expense, and cash flow guidance from June 18 remains unchanged; they also said additional capital will be needed and they are exploring funding options in the second half.
Christophe Bourdon framed the period as a difficult reset after the June 18 FDA Complete Response Letter for NPC, calling the news very disappointing and saying it forced hard decisions. He emphasized that the company believes arimoclomol still has meaningful therapeutic potential in NPC, citing statistically significant and clinically meaningful effects and a good safety profile up to 36 months. His tone was defensive but determined: Orphazyme is now narrowly focused on the two registration milestones in Europe and the U.S., while also working to extend Early Access availability for patients.
Anders Vadsholt focused on capital preservation and the cost reset. He said the restructuring should reduce total operating expenses by approximately 60%, with significant expense reductions expected by the end of 2021, though some restructuring costs will continue in the second half. He reported DKK 13.2 million in first-half revenues, DKK 479 million in operating expenses, DKK 265 million in R&D expense, a net loss of DKK 454 million, and DKK 334 million in cash at period end. He also reiterated full-year revenue guidance of DKK 30 million to DKK 40 million from France and said more capital is required to advance arimoclomol.
The only analyst question asked whether Orphazyme was doing any business development or partnering work beyond arimoclomol over the next 6 to 12 months. Bourdon answered that the company is currently solely focused on the two registration milestones, one in Europe and one in the U.S., and that it would assess other options only once there is more clarity. The Q&A reinforced that near-term strategy is highly concentrated and that management is not prioritizing broader pipeline expansion right now.
The positive case from this call is that Orphazyme still sees a clear path to potential approvals in Europe and the U.S., and management sounded confident in arimoclomol’s data package. More than 100 patients are already in Early Access, the company expects a CHMP opinion by year-end, and it believes the restructuring can materially lower burn while preserving the key functions needed for approval.
The main risk is the FDA CRL, which has already forced a major strategic reset and raised the need for additional financing. Cash was DKK 334 million at June 30, and management explicitly said more capital will be needed to reach commercialization. The company also discontinued other programs, leaving it heavily dependent on a single asset and on regulatory outcomes that are not yet secured.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 73.6%
- Shares Outstanding
- 53.75K
- Float Shares
- 39.57K
Our OZYMF coverage
Recent articles, reports, and earnings notes.
No research on OZYMF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OZYMF report →Orphazyme completes sale of substantially all of its assets and business activities to KemPharm
globenewswire.com · May 31
Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.
globenewswire.com · May 15
Why Entera Bio, Orphazyme, Bellerophon Are Moving Today
benzinga.com · Jun 23
Kim Stratton, CEO, resigns from Orphazyme
globenewswire.com · Dec 10
CytRx Highlights Orphazyme's Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C
businesswire.com · Nov 11
Orphazyme closes its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe
globenewswire.com · Oct 1
Orphazyme announces U.S. FDA acceptance and Priority Review of New Drug Application for arimoclomol for Niemann-Pick disease Type C
globenewswire.com · Sep 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.